[go: up one dir, main page]

WO2010030865A3 - Perte de fbxw7, un biomarqueur de la sensibilité au traitement de tumeurs par des inhibiteurs du mtor - Google Patents

Perte de fbxw7, un biomarqueur de la sensibilité au traitement de tumeurs par des inhibiteurs du mtor Download PDF

Info

Publication number
WO2010030865A3
WO2010030865A3 PCT/US2009/056641 US2009056641W WO2010030865A3 WO 2010030865 A3 WO2010030865 A3 WO 2010030865A3 US 2009056641 W US2009056641 W US 2009056641W WO 2010030865 A3 WO2010030865 A3 WO 2010030865A3
Authority
WO
WIPO (PCT)
Prior art keywords
mtor
fbxw7
biomarker
tumors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/056641
Other languages
English (en)
Other versions
WO2010030865A2 (fr
Inventor
Jian-hua MAO
Allan Balmain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2010030865A2 publication Critical patent/WO2010030865A2/fr
Publication of WO2010030865A3 publication Critical patent/WO2010030865A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes permettant de déterminer si un patient atteint d'un cancer présente ou non un gène Fbxw7 muté (mutations ponctuelles, polymorphismes, délétions ou additions, y compris absence du gène par délétion complète et silençage du promoteur) et ainsi de déterminer si le patient est éligible ou non à un traitement par inhibiteur du mTOR. La présente invention porte aussi sur une méthode de détermination du risque de cancer par comparaison des quantités relatives des constituants en amont et en aval du mTOR dans la voie de signalisation du mTOR.
PCT/US2009/056641 2008-09-11 2009-09-11 Perte de fbxw7, un biomarqueur de la sensibilité au traitement de tumeurs par des inhibiteurs du mtor Ceased WO2010030865A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19192108P 2008-09-11 2008-09-11
US61/191,921 2008-09-11

Publications (2)

Publication Number Publication Date
WO2010030865A2 WO2010030865A2 (fr) 2010-03-18
WO2010030865A3 true WO2010030865A3 (fr) 2010-07-22

Family

ID=42005760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/056641 Ceased WO2010030865A2 (fr) 2008-09-11 2009-09-11 Perte de fbxw7, un biomarqueur de la sensibilité au traitement de tumeurs par des inhibiteurs du mtor

Country Status (1)

Country Link
WO (1) WO2010030865A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10006089B2 (en) 2011-03-02 2018-06-26 Beth Israel Deaconess Medical Center, Inc. MCL-1 as a therapeutic target in SCFFBW7 deficient neoplasm
WO2012130720A2 (fr) * 2011-03-28 2012-10-04 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Prédiction de la sensibilité vis-à-vis d'inhibiteurs de pi3k/mtor
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2016104777A1 (fr) * 2014-12-26 2016-06-30 国立大学法人九州大学 Procédé de traitement d'un cancer
CN105112515A (zh) * 2015-08-14 2015-12-02 深圳市众偱精准医学研究院 Fbxw7基因及表达产物在肾癌检测、肾癌药物制备中的用途
US20230042367A1 (en) * 2019-12-06 2023-02-09 The Governing Council Of The University Of Toronto Methods and compositions for treating cancers having f-box and wd-repeat protein 7 (fbxw7) alterations and/or cyclin l1 (ccnl1) gain or amplification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061213A2 (fr) * 2006-11-16 2008-05-22 Genentech, Inc. Variations génétiques associées à des tumeurs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061213A2 (fr) * 2006-11-16 2008-05-22 Genentech, Inc. Variations génétiques associées à des tumeurs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ERIC S. CALHOUN ET AL.: "BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer.", AMERICAN JOURNAL OF PATHOLOGY., vol. 163, no. 4, October 2003 (2003-10-01), pages 1255 - 1260 *
JIAN-HUA MAO ET AL.: "FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.", SCIENCE., vol. 321, no. 5895, 12 September 2008 (2008-09-12), pages 1499 - 1502 *
MARKUS WELCKER ET AL.: "The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.", PROCEEDINGS OF NATIONAL ACADEMY OF SCIENCES OF UNITED STATES OF AMERICA., vol. 101, no. 24, 15 June 2004 (2004-06-15), pages 9085 - 9090 *
PAZIT POLAK ET AL.: "mTOR and the control of whole body metabolism.", CURRENT OPINION IN CELL BIOLOGY., vol. 21, no. 2, 2 March 2009 (2009-03-02), pages 209 - 218 *
RICHARD S. MASER ET AL.: "Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.", NATURE., vol. 447, no. 7147, 21 June 2007 (2007-06-21), pages 966 - 972 *
SAHOKO MATSUOKA ET AL.: "Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL.", GENES AND DEVELOPMENT., vol. 22, no. S, 15 April 2008 (2008-04-15), pages 986 - 991 *

Also Published As

Publication number Publication date
WO2010030865A2 (fr) 2010-03-18

Similar Documents

Publication Publication Date Title
AU2019229353A1 (en) Mutant calreticulin for the diagnosis of myeloid malignancies
WO2010030865A3 (fr) Perte de fbxw7, un biomarqueur de la sensibilité au traitement de tumeurs par des inhibiteurs du mtor
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
WO2012006589A3 (fr) Procédés et compositions pour l'identification, l'évaluation et le traitement de cancers associés à des signaux hedgehog
WO2008063769A3 (fr) Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations
WO2014140933A3 (fr) Procédé de pronostic et de traitement de métastases cancéreuses
WO2013153458A3 (fr) Méthode de pronostic et de traitement de métastases cancéreuses
EP3831964A3 (fr) Méthode d'utilisation d'une expression génique pour déterminer la probabilité du résultat clinique d'un cancer des reins
MX2013004086A (es) Metodos para inhibir proliferacion celular en cancers accionados por egfr.
NZ612483A (en) Drug selection for malignant cancer therapy using antibody-based arrays
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
WO2009015050A3 (fr) Profil d'expression génique pour prédire la survie d'une patiente atteinte d'un cancer des ovaires
WO2011153545A3 (fr) Signature d'expression génique utilisée pour prédire une réponse à une chimiothérapie lors d'un cancer du sein
WO2022043930A3 (fr) Biomarqueurs pour la thérapie anticancéreuse utilisant des antagonistes de mdm2
WO2012079059A3 (fr) Pronostic du cancer du sein après traitement
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2012154567A3 (fr) Signature d'invasion humaine pour le pronostic d'un risque métastasique
EP4286847A3 (fr) Anomalies génétiques dans des dyscrasies de cellules du plasma
WO2009073575A3 (fr) Procédés de traitement des troubles prolifératifs cellulaires induits
WO2013169771A3 (fr) Procédés et compositions pour le pronostic et le traitement de leucémie récurrente
EP3502702A3 (fr) Prévision de la récurrence du cancer de la vessie par signature de protéine dans des échantillons de tissus
Kang et al. Silencing of miR-137 by aberrant promoter hypermethylation in surgically resected lung cancer
WO2010102160A3 (fr) Procédé de diagnostic utilisant palb2
Yuan et al. SEMA3G, downregulated by ncRNAs, correlates with favorable prognosis and tumor immune infiltration in kidney renal clear cell carcinoma
WO2014066860A3 (fr) Méthodes de pronostic et de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09813664

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09813664

Country of ref document: EP

Kind code of ref document: A2